TP53 and B-cell non-Hodgkin lymphoma: Thus, identification of alterations in TP53 and Hippo pathways or novel gene fusions that are implicated in drug resistance and poor prognosis may guide pharmacological interventions by targeting the alterations and thus improve survival of B-cell lymphoma patients.